Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ZEPHYR: Ziltivekimab in Coronary Atherosclerosis Post-AMI
NCT07276282Phase 3Recruiting
- Sponsor
- ECRI
- Start
- Dec 2025
- Primary completion
- Sep 2028
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of ziltivekimab in Coronary atherosclerosis (CAD), acute myocardial infarction (AMI), sponsored by ECRI. Started Dec 2025; status: recruiting.
02
Drugs
ziltivekimab
03
Conditions
Coronary atherosclerosis (CAD)acute myocardial infarction (AMI)
Beyond the preview
Go deeper on NCT07276282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07276282.